Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery.

@article{Tanaka2003PeptideVF,
  title={Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery.},
  author={Shoko Tanaka and Mamoru Harada and Takashi Mine and Masanori Noguchi and Rumi Gohara and Koichi Azuma and Mayumi Tamura and Akira Yamada and Akiko Morinaga and Misa Nishikori and Kazuko Katagiri and Kyogo Itoh and Hideaki Yamana and Takashi Hashimoto},
  journal={Journal of immunotherapy},
  year={2003},
  volume={26 4},
  pages={357-66}
}
Identification of antigenic peptides expressed on cancer cells enables us to treat cancer patients with peptide-based immunotherapy. Although optimal protocols for peptide-based vaccines have not yet been elucidated, boosting the immune system could be a better approach than priming the immune system to elicit prompt and potent peptide-specific T-cell responses in cancer patients. With this possibility in mind, the authors undertook a clinical trial in which cancer patients were vaccinated with… CONTINUE READING